trending Market Intelligence /marketintelligence/en/news-insights/trending/03zaPeBTkiVgLMpAilo65A2 content esgSubNav
In This List

Aytu BioScience to distribute male infertility diagnostic platform in Asia

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Aytu BioScience to distribute male infertility diagnostic platform in Asia

Aytu BioScience Inc. signed an agreement with five Asian specialty medical distributors for the commercialization of its MiOXSYS System, a male infertility diagnostic platform.

The company's initial Asian network of distributors includes Naka International Corp. in Japan, CNC Biotech Inc. in Korea, Chun Fo Pharmaceutical in Hong Kong and Macau and Trivector Biomed LLP and Neoteric Medical Systems in India.

The company is currently seeking regulatory clearance for its product in the U.S. through FDA's 510(k) de novo pathway. MiOXSYS is an in vitro diagnostic platform that assesses the level of oxidative stress in semen to help diagnose infertility.